In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an ...

Valued at a market cap of $9.6 billion, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company that ...

As the 2020 pandemic became a distant memory and millions of Americans returned back to their old lives, some were left ...

The deal marks 10-year-old Moderna’s first acquisition. The company develops mRNA therapeutics and vaccines, and the move will enable it to utilise the synthetic biology and enzyme tech of 2018 ...